Biosimilar

BIOLOGICAL4 trials

Sponsors

Opal Rheumatology Ltd., McGill University Health Centre/Research Institute of the McGill University Health Centre, Merck, Pfizer

Conditions

ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER - certain type of lungcancerAnkylosing SpondylitisCrohn's DiseaseHealthy Volunteers (arthritis, skin conditions, digestive disorders) anti inflammation biosimilarPsoriatic ArthritisRheumatoid ArthritisUlcerative Colitis

Phase 3

A PHASE 3 RANDOMIZED, DOUBLE-BLIND STUDY OF PF-06439535 PLUS PACLITAXEL-CARBOPLATIN AND BEVACIZUMAB PLUS PACLITAXEL-CARBOPLATIN FOR THE FIRST-LINE TREATMENT OF PATIENTS WITH ADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER

Active, not recruitingNL-OMON45020

PfizerADVANCED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER - certain type of lungcancer

Start: 2015-10-12Target: 20Updated: 2024-02-28

Unknown Phase

A Phase I, Randomized, Double-Blind, Parallel Group, Single-Dose Trial to Compare the Pharmacokinetics, Safety, Tolerability and Immunogenicity of Two Formulations of MSB11022 (Proposed Adalimumab Biosimilar)

Active, not recruitingNL-OMON43181

MerckHealthy Volunteers (arthritis, skin conditions, digestive disorders) anti inflammation biosimilar

Start: 2016-10-24Target: 30Updated: 2024-02-28

Investigating the Utilisation and Effectiveness of Originator and Biosimilar Anti-TNF Agents

Opal Rheumatology Ltd.Ankylosing Spondylitis, Psoriatic Arthritis, Rheumatoid Arthritis

Start: 2018-03-01End: 2021-12-31Target: 5000Updated: 2018-03-21

Comparative Effectiveness and Safety of Biosimilar and Legacy Drugs

McGill University Health Centre/Research Institute of the McGill University Health CentreAnkylosing Spondylitis, Crohn's Disease, Rheumatoid Arthritis +1

Start: 2018-11-26End: 2022-12-31Target: 800Updated: 2020-06-02